TAIPEI, TAIWAN – With the official opening in Taiwan of its new preclinical and early clinical quantity biopharmaceutical plant last week, another milestone has been reached in rapid fashion by the upstart JHL Biotech Co. Ltd. Read More
HONG KONG – A novel class of antitubercular drugs, the indol carboxamides, has been shown safe and effective against clinical Mycobacterium tuberculosis isolates in preclinical studies, report Novartis Institute for Tropical Diseases (NITD) in Singapore researchers in the latest issue of Science Translational Medicine. Read More
HONG KONG – The U.S. FDA plans to add 10 more investigators to its China office to enhance its monitoring of Chinese exports of pharmaceuticals to the U.S. Read More
Daiichi Sankyo Co. Ltd., of Tokyo, reported results of a prespecified subgroup analysis of 771 cancer patients enrolled in the Phase III Hokusai-VTE study, showing that subjects with either a history of cancer or with active cancer treated with once-daily Factor Xa inhibitor edoxaban had a numerically lower incidence of recurrent symptomatic venous thromboembolism compared to warfarin (3.7 percent vs. 7.1 percent). Read More
